Sell Alert: Focusing on the Big Picture When the Big Picture Matters

Dear Biotech Frontiers Subscribers: There is one big question today that no investor can ignore or avoid: Is inflation in the U.S. on its way down… or is it set to rebound? This question matters to every asset class – stocks, bonds, real estate, commodities, precious metals, crypto, art – and to every single investment
Read More …

Bulls Balls

For only the third time in history, a new energy drink has surpassed the billion-dollar mark in annual sales in the U.S. But this company is not only taking market share from its two main competitors but it’s expanding the size of the overall market.
Read More …

Action to Take: Sell Half of Kodiak Sciences

Dear Biotech Frontiers subscribers: Shares of Kodiak Sciences (Nasdaq: KOD), part of our original basket of 10-negative-enterprise-value biotech stocks, are up about 100%. We recommended Kodiak at $3.16 per share. Today, shares are trading in the range $6.15 to $6.35. There is no specific news that has driven the re-rating in Kodiak, and the stock
Read More …

The Basement Experiment That Became a $2 Billion Best-Seller

In a world of constant change, one thing remains steady: Americans love for chocolate. Today we focus on the ultimate “forever stock.” Backed up by more than a century of brand power, this business will remain as relevant for our children and grandchildren as it was for our parents and grandparents.
Read More …

Two Important Updates on Iovance Biotherapeutics

Dear Biotech Frontiers Subscribers: We have two timely pieces of news to digest. 1. This past Friday, February 16, the Food and Drug Administration (“FDA”) granted Iovance Biotherapeutics’ (Nasdaq: IOVA) lifileucel therapy accelerated approval for advanced melanoma, making it the first and only tumor-infiltrating lymphocyte (“TIL”) treatment available for cancer. Lifileucel’s approval is an important
Read More …